Clinical Research Directory

Inclusion Criteria for AL-amyloid subjects: * Age \> 18 years * Willing and able to provide consent * AL-CA: Diagnosis of systemic light chain amyloidosis by standard criteria: Immunofixation of serum, serum free light chain (FLC) assay, a biopsy of fat pad/bone marrow, or organ biopsy, followed by typing of the light chain using immunohistochemistry or immunogold assay with confirmation by mass spectroscopy as needed AND * Proof of cardiac involvement by AL amyloidosis * Abnormal cardiac biomarkers: abnormal high sensitivity TnT 5th generation levels (\> 15 ng/L) or abnormal age-appropriate NT-proBNP (abnormal values: \< 50 years: \> 450 pg/ml; 50-75 years: \> 900 pg/ml; \> 75 years: \> 1800 pg/ml) OR * Abnormal echocardiogram (wall thickness \> 12 mm in the absence of other causes of increased LV wall thickness) OR * Abnormal CMR (wall thickness \> 12 mm, extracellular volume \> 0.40 or typical CMR appearance of cardiac amyloidosis with difficulty nulling images and non-coronary distribution late gadolinium enhancement) OR * Positive endomyocardial biopsy Inclusion Criteria for ATTR-amyloid subjects: * Age \> 18 years * Willing and able to provide consent * ATTR-CA: Diagnosis of either wildtype or hereditary transthyretin cardiac amyloidosis by standard criteria: Endomyocardial biopsy followed by typing of the transthyretin amyloidosis using immunohistochemistry or immunogold assay with confirmation by mass spectroscopy as needed * Extracardiac biopsy with typical cardiac imaging findings * Hereditary ATTR amyloidosis by genetic testing OR * Grade 2 or grade 3 myocardial uptake of 99mTc-PYP if AL amyloidosis is excluded Inclusion Criteria for recent myocardial infarction subjects: * Age \> 18 years * Willing and able to provide consent * Recent MI: Diagnosis of recent type 1 myocardial infarction by standard criteria * More than 6 weeks from diagnosis of MI but within 6 months * Imaging evidence of loss of viable myocardium or persistent regional wall motion abnormalities in a pattern consistent with an ischemic etiology in more than one segment Inclusion Criteria for hypertrophic cardiomyopathy subjects: * Age \> 18 years * Willing and able to provide consent * Hypertrophic cardiomyopathy: Diagnosis of hypertrophic cardiomyopathy by standard criteria * MRI evidence of late gadolinium enhancement Inclusion Criteria for recent healthy control subjects: * Age \> 18 years * Willing and able to provide consent * No known cardiac amyloidosis or recent myocardial infarction Exclusion Criteria: * Dialysis * NYHA (New York Heart Association) Class IV * Acute myocardial infarction within 6 weeks * Pregnancy or nursing * History of adverse events from or allergy to gadolinium contrast media * Hemodynamic instability * Severe claustrophobia despite use of sedatives * Decompensated heart failure (unable to lie flat for 1 hour) * Concomitant clinically significant non-ischemic non-amyloid heart disease (valvular heart disease or dilated cardiomyopathy) * Body weight over limit for MRI table (\>300 lbs) * Contraindications for MRI (including non-compatible cardiac implantable electronic devices, drug infusion pumps, and metallic or electric implants) * Any other reason determined by the investigator to be unsuitable for the study